Tiziana Life Sciences LtdNASDAQ:TLSANASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE0.7440
- TODAY'S CHANGE (%)0.0630 (9.2511%)
- Bid / Lots0.7010/ 10
- Ask / Lots0.7382/ 1
- Open / Previous Close0.7220 / 0.6810
- Day Range
- 52 Week Range
- Volume109,991
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | TLSA |
|---|---|---|
| 09:32 ET | 5052 | 0.722 |
| 09:38 ET | 3400 | 0.671 |
| 09:41 ET | 250 | 0.6721 |
| 09:50 ET | 3402 | 0.71 |
| 09:57 ET | 1525 | 0.700576 |
| 10:03 ET | 2500 | 0.6721 |
| 10:10 ET | 500 | 0.7 |
| 10:12 ET | 20885 | 0.74 |
| 10:15 ET | 2302 | 0.739 |
| 10:21 ET | 300 | 0.730928 |
| 10:24 ET | 400 | 0.73 |
| 10:26 ET | 10844 | 0.74 |
| 10:30 ET | 3020 | 0.76 |
| 10:35 ET | 100 | 0.74 |
| 10:37 ET | 194 | 0.74 |
| 10:42 ET | 500 | 0.749652 |
| 10:46 ET | 200 | 0.74 |
| 11:08 ET | 135 | 0.749384 |
| 11:11 ET | 600 | 0.74 |
| 11:22 ET | 160 | 0.7461 |
| 11:26 ET | 100 | 0.74 |
| 11:33 ET | 300 | 0.740101 |
| 11:51 ET | 200 | 0.7401 |
| 12:03 ET | 4000 | 0.744951 |
| 12:09 ET | 400 | 0.740487 |
| 12:12 ET | 11500 | 0.75 |
| 12:16 ET | 133 | 0.7487 |
| 12:36 ET | 500 | 0.741 |
| 12:38 ET | 200 | 0.75 |
| 12:57 ET | 100 | 0.7462 |
| 01:08 ET | 3329 | 0.74 |
| 01:10 ET | 100 | 0.74 |
| 01:12 ET | 100 | 0.7403 |
| 01:37 ET | 100 | 0.74 |
| 01:46 ET | 1000 | 0.73001 |
| 01:51 ET | 1000 | 0.7306 |
| 01:55 ET | 867 | 0.74 |
| 02:08 ET | 100 | 0.7499 |
| 02:18 ET | 100 | 0.7305 |
| 02:24 ET | 2163 | 0.748 |
| 02:26 ET | 100 | 0.75 |
| 02:36 ET | 3043 | 0.74 |
| 02:40 ET | 1090 | 0.74 |
| 02:49 ET | 856 | 0.7491 |
| 02:51 ET | 351 | 0.74 |
| 02:54 ET | 2100 | 0.73 |
| 03:03 ET | 2032 | 0.75 |
| 03:12 ET | 100 | 0.749 |
| 03:18 ET | 999 | 0.73 |
| 03:36 ET | 500 | 0.7335 |
| 03:39 ET | 330 | 0.73 |
| 03:43 ET | 673 | 0.749 |
| 03:48 ET | 150 | 0.730101 |
| 03:52 ET | 100 | 0.7495 |
| 03:54 ET | 400 | 0.73 |
| 03:57 ET | 578 | 0.7338 |
| 03:59 ET | 127 | 0.744 |
May 13, 2024
Tiziana Life Sciences Files for Orphan Drug Designation for Intranasal Foralumab, from 7:00AM ET on Monday May 13, 2024 by Dow Jones
7:00AM ET on Monday May 13, 2024 by Dow Jones
Apr 25, 2024
Tiziana Life Sciences Reports Positive 3-Month Neuroimaging Scores in Multiple Sclerosis Patients Receiving Intranasal Foralumab, from 10:00AM ET on Thursday Apr 25, 2024 by Dow Jones
10:00AM ET on Thursday Apr 25, 2024 by Dow Jones
Apr 23, 2024
Apr 22, 2024
Apr 19, 2024
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Tiziana Life Sciences Ltd | 69.6M | -5.0x | --- |
Landos Biopharma Inc | 69.7M | -5.6x | --- |
Intensity Therapeutics Inc | 69.9M | -4.4x | --- |
Maia Biotechnology Inc | 68.1M | -2.1x | --- |
Tempest Therapeutics Inc | 71.5M | -1.8x | --- |
Regencell Bioscience Holdings Ltd | 67.8M | -8.9x | --- |
Company Information
Tiziana Life Sciences Ltd. is a United Kingdom-based clinical-stage biotechnology company. The Company develops transformative therapies for neurodegenerative and lung diseases. Its clinical pipeline includes drug assets for secondary progressive multiple sclerosis, Crohn's Disease and KRAS+ NSCLC. Its pipeline candidates include Foralumab (TZLS-401), Anti IL-6R mAb (TZLS-501) and Milciclib (TZLS-201). Foralumab (TZLS-401) is a fully human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn’s and neurodegenerative diseases. Its Anti IL-6R mAb (TZLS-501), a fully human mAb binds to both membrane-bound and soluble forms of IL-6R, an inflammatory cytokine driving chronic inflammation associated with autoimmune disease and cancer, reducing circulating levels of the IL-6 cytokine. Milciclib is a potent, small molecule inhibitor of multiple cyclin-dependent kinases (CDKs), tropomycinreceptor kinases and Src family kinases controlling cell growth and malignant progression of cancer.
Contact Information
- Headquarters
- 3Rd Floor, 11-12 St. James's SquareLONDON, United Kingdom SW1Y 4LB
- Phone
- 207-495-2379
- Fax
- ---
Executives
- Executive Chairman of the Board
- Gabriele Cerrone
- Chief Executive Officer, Chief Scientific Officer, Executive Director
- Kunwar Shailubhai
- Finance Director
- Keeren Shah
- Senior Director, CMC and Non - Clinical Development
- Jules Jacob
- Chief Development Officer
- William Clementi
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $69.6M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 102.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.37 |
EPS | $-0.15 |
Book Value | $0.19 |
P/E Ratio | -5.0x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
